Compound Evidence File
#EC-2026-0454
1-Boc-4-(4-fluorophenylamino)piperidine CAS 288573-56-8
Filed under Raw Materials. The bureau holds 113 laboratory returns for this compound from 35 distinct subjects. Scores below are per-subject aggregates; open a subject row for the underlying evidence.
Cross-Index
Subjects Shipping This Compound
35 SUBJECTS| Subject | Grade | Samples | Mean | Min | Max | First seen | Last seen |
|---|---|---|---|---|---|---|---|
| Tianjin Finder Chemical TFCCASE #VI-2026-0693 | A | 4 | 10.0 | 9.9 | 10.0 | 14 Nov 2025 | 16 Apr 2026 |
| QYAOBIOCASE #VI-2026-0861 | A | 4 | 10.0 | 10.0 | 10.0 | 15 Feb 2026 | 12 Jul 2026 |
| BachemCASE #VI-2026-0314 | A | 4 | 10.0 | 9.9 | 10.0 | 3 Apr 2026 | 28 Jun 2026 |
| Shanghai Sigma AudleyCASE #VI-2026-0505 | A | 4 | 10.0 | 10.0 | 10.0 | 4 Mar 2026 | 23 Jul 2026 |
| Thermo Fisher ScientificCASE #VI-2026-0142 | A | 4 | 10.0 | 10.0 | 10.0 | 15 Mar 2026 | 4 Aug 2026 |
| Hubei JianxiangCASE #VI-2026-0048 | A | 3 | 10.0 | 9.9 | 10.0 | 13 Nov 2025 | 20 Jun 2026 |
| WuXi TIDESCASE #VI-2026-0335 | A | 3 | 10.0 | 9.9 | 10.0 | 18 Nov 2025 | 21 Apr 2026 |
| Hybio PharmaceuticalCASE #VI-2026-0065 | A | 3 | 10.0 | 10.0 | 10.0 | 4 Feb 2026 | 8 May 2026 |
| Sigma-AldrichCASE #VI-2026-0829 | A | 3 | 10.0 | 9.9 | 10.0 | 7 Feb 2026 | 16 Jul 2026 |
| Shanghai ERP BiotechnologyCASE #VI-2026-0936 | A | 2 | 10.0 | 10.0 | 10.0 | 3 Jul 2026 | 4 Jul 2026 |
| Kerui PeptidesCASE #VI-2026-0626 | A | 2 | 10.0 | 10.0 | 10.0 | 1 Feb 2026 | 12 Jul 2026 |
| Mokemei BiotechnologyCASE #VI-2026-0540 | A | 2 | 10.0 | 10.0 | 10.0 | 22 May 2026 | 28 May 2026 |
| Flourishglobal PeptideCASE #VI-2026-0630 | A | 2 | 10.0 | 10.0 | 10.0 | 24 Jun 2026 | 27 Jun 2026 |
| HomopeptideCASE #VI-2026-0760 | A | 7 | 9.9 | 9.9 | 10.0 | 21 May 2026 | 21 May 2026 |
| GenScript PeptidesCASE #VI-2026-0860 | A | 4 | 9.9 | 9.9 | 10.0 | 2 Feb 2026 | 15 Jun 2026 |
| SinoPepCASE #VI-2026-0387 | A | 4 | 9.9 | 9.9 | 10.0 | 11 Apr 2026 | 8 Jun 2026 |
| AsymchemCASE #VI-2026-0091 | A | 4 | 9.9 | 9.9 | 9.9 | 20 Apr 2026 | 23 Jul 2026 |
| Sangon BioCASE #VI-2026-0671 | A | 2 | 9.9 | 9.9 | 9.9 | 22 Nov 2025 | 11 Jun 2026 |
| JEEP PeptidesCASE #VI-2026-0457 | A | 2 | 9.9 | 9.9 | 10.0 | 4 Jun 2026 | 10 Jun 2026 |
| Shanghai Wibson BiotechnologyCASE #VI-2026-0379 | A | 2 | 9.9 | 9.9 | 10.0 | 12 Jun 2026 | 20 Jun 2026 |
| Chinese Peptide CompanyCASE #VI-2026-0184 | A | 2 | 9.9 | 9.9 | 9.9 | 22 Jan 2026 | 9 Jun 2026 |
| PolyPeptide GroupCASE #VI-2026-0143 | A | 2 | 9.9 | 9.9 | 10.0 | 25 May 2026 | 10 Jun 2026 |
| AmbioPharmCASE #VI-2026-0177 | A | 2 | 9.9 | 9.9 | 10.0 | 13 May 2026 | 23 Jun 2026 |
| Shanghai Sigma Audley SSACASE #VI-2026-0486 | A | 8 | 9.1 | 7.8 | 10.0 | 25 May 2026 | 25 May 2026 |
| Qingdao Sigma Chemical QSCCASE #VI-2026-0538 | A | 8 | 8.6 | 7.0 | 9.7 | 23 May 2026 | 23 May 2026 |
| Nantong Guangyuan Chemical GYCCASE #VI-2026-0284 | A | 7 | 8.6 | 7.5 | 9.5 | 24 May 2026 | 24 May 2026 |
| Wuhan Wansheng Bio (WWB)CASE #VI-2026-0594 | A | 2 | 8.4 | 8.2 | 8.6 | 24 May 2026 | 24 May 2026 |
| Yiwu Aozuo Trading CoCASE #VI-2026-0798 | X | 7 | 8.4 | 6.0 | 10.0 | 3 Jul 2025 | 19 Jan 2026 |
| Pura PeptidesCASE #VI-2026-0307 | X | 1 | 7.9 | 7.9 | 7.9 | 2 Apr 2025 | 2 Apr 2025 |
| Glbiochem (Shanghai)CASE #VI-2026-0704 | A | 4 | 7.8 | 6.8 | 8.8 | 21 May 2026 | 21 May 2026 |
| Hangzhou Youngpeptide Biotechnology HYBCASE #VI-2026-0347 | X | 1 | 7.3 | 7.3 | 7.3 | 11 Jun 2025 | 11 Jun 2025 |
| UWA Elite PeptidesCASE #VI-2026-0130 | X | 1 | 6.0 | 6.0 | 6.0 | 14 Jan 2025 | 14 Jan 2025 |
| Haikou Mingheng BiotechnologyCASE #VI-2026-0126 | X | 1 | 5.2 | 5.2 | 5.2 | 9 Jun 2025 | 9 Jun 2025 |
| SubQ SocietyCASE #VI-2026-0716 | X | 1 | 1.6 | 1.6 | 1.6 | 13 Jun 2025 | 13 Jun 2025 |
| Wuhan Newtop BiotechCASE #VI-2026-0676 | X | 1 | 0.0 | 0.0 | 0.0 | 14 Jan 2025 | 14 Jan 2025 |
Open any subject to view the batch-level evidence for 1-Boc-4-(4-fluorophenylamino)piperidine CAS 288573-56-8 alone.